NCT00668863 - Study Of Sunitinib With FOLFIRI In Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Unresectable or Metastatic Colorectal Cancer

Interventions

DRUG

FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)

FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

DRUG

Sunitinib

37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.

Trial Locations (10)

Unknown

Pfizer Investigational Site, Nagoya

Pfizer Investigational Site, Chiba

Pfizer Investigational Site, Matsuyama

Pfizer Investigational Site, Sapporo

Pfizer Investigational Site, Minoh/Osaka

Pfizer Investigational Site, Kochi

Pfizer Investigational Site, Saku

Pfizer Investigational Site, Osakasayama-shi

Pfizer Investigational Site, Takatsuki

Pfizer Investigational Site, Shimotsuke-shi